NEW YORK (GenomeWeb news) – Quotient Bioresearch said today that it will buy three mass spectrometers from Thermo Fisher Scientific.
Cambridge, UK-based Quotient Bioresearch will use the three new LTQ Orbitrap XL mass spectrometers for use in its drug development and sports testing services.
The company said the new tools are part of its program to continue to develop its metabolite identification services, in part because the US Food and Drug Administration is “driving the need to identify and quantitate key metabolites at the early stage of the drug development process.”
The TFS mass spectrometers support small-molecule metabolite profiling and will enable Quotient Bioresearch to extract metabolite information from early toxicology and clinical research samples.
Financial terms of the agreement were not released.